Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The latest research highlights in lymphoma

APAO 22nd Annual Oncology Symposium

29 Aug - 1 Sep 2019

Published: 17 Oct 2019

Views: 733

Rating:

Save

Corinne Williams, PA-C, President of APAO

Corrine Williams speaks to ecancer at the APAO 2019 meeting in Boston about the latest research in lymphoma.

She outlines the benefits of oral oncolytics, but also the fact that they are currently an indefinite treatment. The CLL-14 trial is looking to change this.

Corrine finishes by discussing the latest long term data on ibrutinib.

Related Videos

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms ( Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Ponatinib is better than imatinib for frontline treatment of newly diagnosed...

Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia ( Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

More from ecancer